Risk Factors

EarlyCDT^™-Lung is designed to aid early detection, specifically for asymptomatic individuals deemed by a physician at increased risk of developing lung cancer. While everyone carries some risk of developing lung cancer, you could be at increased risk if you answer “yes” to one or more of the following questions.

The process recommended by your health-care provider is designed to detect a lung tumor as early as possible. It is important to remember that EarlyCDT^™-Lung has been developed to help detect the presence of autoantibodies to tumor antigens which have been reported to be detectable up to five years before a tumor has become definable.¹ Early detection improves the potential for a good outcome. If you are at increased risk, EarlyCDT^TM-Lung could be invaluable in early detection. It is important to realize that EarlyCDT^™-Lung cannot be guaranteed to detect all cases of lung cancer. Early detection has been shown to improve mortality in some types of cancer (e.g. breast, colon, cervical). In lung cancer early detection has not been proven to reduce mortality.

Should you have EarlyCDT?

This is not meant to be a comprehensive questionnaire. Please talk to your physician about your risk of developing lung cancer.
US Patent No 7,402,403

Sources:
¹Zhong L, Coe SP, Stromberg AJ, et al. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thor Oncol 2006; 1:513-519